Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with ...

The Media Front: Why OpenAI Bought Tech Talk Show TBPN

In this week's column, OpenAI buys TBPN, TMZ ambushes Congress, NYT cuts ties with writer, DC media scramble and a ‘60 ...